Zhongheng Group: Zhongheng Innovation, a wholly-owned subsidiary, acquired a technology for treating chronic heart failure with an investment of 55 million yuan.

date
04/08/2025
Zhongheng Group announced that its wholly-owned subsidiary Zhongheng Innovation has acquired, through acquisition, the technology of a drug for treating chronic heart failure from China Rongtong Scientific Research Group Co., Ltd., which was publicly listed for transfer on the Shanghai Technology Exchange. The transaction price was 55 million RMB. This transaction does not constitute a related party transaction or a major asset restructuring. The transaction has been approved at the 29th meeting of the 10th Board of Directors of the company and does not require approval from the shareholders' meeting.